Further results demonstrate that the cytotoxicity of CD8+ Tregs in tumor cell killing is the basis of GVL effects and that the combination of CD4+ Tregs and CD8+ Tregs is an ideal therapy that would more effectively prevent GVHD and preserve GVL effects (21). Here, CD4 is linked to graft versus host disease.